ubmslateCN-logo-ubm

CN Mobile Logo

Search form

Topics:

Oncology and Hematology News and Journal Articles

Isolated Limb Perfusion for Stage III Melanoma: Does It Still Have a Role in the Present Era of Effective Systemic Therapy?

Effective systemic therapy for the treatment of stage III melanoma has emerged. Whether this influences treatment choice in stage III melanoma patients with in-transit metastases is the subject of this review.

Recent Content

Adding bortezomib to lenalidomide and dexamethasone improved progression-free and overall survival in patients with newly diagnosed multiple myeloma who were not planned for immediate stem-cell transplant.

Advanced colorectal cancer patients with BRAF mutations have markedly worse prognosis than non-mutant patients, according to a large analysis. Post-progression survival in particular is worse among BRAF-mutant patients.

Ahead of the 2017 ASCO Gastrointestinal Cancer Symposium in San Francisco, we spoke with Dr. Geoffrey Ku on the advances in systemic therapy for esophageal and gastric cancer.

Patients with metastatic colorectal cancer who engaged in more hours of physical activity at the time of their diagnosis had improvements in both progression-free and overall survival compared with patients who had less physical activity.

Using PET scans during induction chemotherapy for esophageal cancer, researchers were able to assess patient response to treatment and adjust their therapy, leading to an improved rate of pathologic complete response prior to surgery.

The combination of bortezomib and dexamethasone with 160 mg daily ricolinostat, a selective histone deacetylase 6 inhibitor, was well tolerated and active in patients with relapsed/refractory multiple myeloma.

Participation in a training program increased levels of self-confidence for both patients and their partners in performing skin self-examinations to detect melanoma.

By clicking Accept, you agree to become a member of the UBM Medica Community.